NEW YORK (GenomeWeb News) — Enzo Biochem today said the US Patent and Trademark Office believes that a patent application it filed 24 years ago interferes with a patent covering genome sequencing technology that is owned by the California Institute of Technology and licensed exclusively to Applied Biosystems.

 

The USPTO has named Enzo the senior party in the dispute over the technology, which is central to ABI’s sequencing instruments. Enzo claims it filed its patent in 1982.